8-K: Vistagen Reports Positive Data for Fasedienol in Social Anxiety Study

Vistagen Therapeutics announces preliminary positive data from the open-label extension of its Phase 3 PALISADE-3 study for fasedienol, showing well-tolerated safety and clinically relevant improvements in social anxiety.

Summary

• Vistagen Therapeutics has released preliminary positive data from the ongoing open-label extension (OLE) of its PALISADE-3 Phase 3 study for fasedienol, an intranasal treatment for social anxiety disorder.
• The data, collected up to May 8, 2026, from 341 participants in the OLE, indicates that fasedienol nasal spray, used as needed up to six times daily for up to 12 months, was well-tolerated.
• No new drug-related safety findings were identified, and the discontinuation rate due to adverse events was low at 2.6% (9/341), with no discontinuations attributed to fasedienol.
• Exploratory efficacy data over the first four months showed clinically relevant improvements in social anxiety as measured by both clinician-administered (LSAS) and patient-reported (SPIN) scales.
• Mean LSAS scores improved significantly over four months, with 56% of subjects showing a 20-point improvement by Month 4.
• Mean SPIN scores also improved, with 55% of subjects showing a 10-point improvement by Month 4.
• The company expects topline data for the PALISADE-4 Phase 3 trial in Q2 2026 and for the exploratory Phase 2 Repeat Dose Study in Q3 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed result. While the open-label extension data shows positive safety and efficacy trends for long-term use, the failure to meet the primary endpoint in the main randomized study is a significant setback.

Positives

• Fasedienol nasal spray demonstrated a favorable safety profile in the OLE portion of the PALISADE-3 study, with no new drug-related safety findings over up to 12 months of as-needed use.
• The discontinuation rate due to adverse events was low at 2.6%, with no discontinuations attributed to the drug.
• Over 95% of treatment-emergent adverse events (TEAEs) were mild or moderate.
• Clinically relevant improvements in social anxiety were observed over four months in the OLE, as measured by both the LSAS (mean improvement of 25.4 points by Month 4) and SPIN (mean improvement of 12.4 points by Month 4).
• A significant percentage of participants achieved meaningful improvements: 56% showed a >= 20-point LSAS improvement and 55% showed a >= 10-point SPIN improvement by Month 4.
• Improvements were seen on both fear and avoidance subscales of the LSAS, indicating reduced fear and avoidance in daily life situations.
• Subjects who did not respond in the randomized portion of PALISADE-3 showed comparable improvements in the OLE, suggesting potential benefit for a broader patient group.

Negatives

• The primary endpoint of the randomized portion of the PALISADE-3 study (single-dose public speaking challenge) was not met, showing no significant difference between fasedienol and placebo on the SUDS scale.
• Secondary endpoints in the randomized portion of PALISADE-3 also did not show a treatment difference.
• Headache (10.9%) and upper respiratory infection (11.4%) were the most common TEAEs, though generally mild to moderate.

Risks

• The randomized portion of the PALISADE-3 study did not meet its primary endpoint, raising questions about the drug's efficacy in acute, single-dose challenge situations.
• There is no guarantee that fasedienol will successfully complete ongoing or future clinical trials, receive regulatory approval, or be commercially successful.
• The company faces substantial risks and uncertainties in the development and commercialization process, including potential delays in clinical trials and regulatory approvals.
• Vistagen's ability to secure adequate financing for continued clinical development is a significant risk.
• The company is dependent on third-party collaborators, which are outside of its full control.
• The scope and enforceability of Vistagen's patents are subject to risk.
• There are potential technical and unexpected hurdles in the development, manufacture, and commercialization of fasedienol.

Future Outlook

Vistagen expects topline data for the PALISADE-4 Phase 3 trial in the second quarter of 2026 and for the exploratory Phase 2 Repeat Dose Study in the third quarter of 2026. The company believes that successful results from PALISADE-4, along with previous data, could support a New Drug Application (NDA) submission to the FDA for the acute treatment of social anxiety disorder.

Management Comments

• "Among our core goals is giving patients the ability to manage their anxiety in the daily life situations that matter most to them. We're continually encouraged by the improvements observed over time when patients in our open-label studies self-administer fasedienol as they feel its needed."
• "The magnitude of improvement on both the LSAS and the SPIN scales through four months of treatment in patients with very severe social anxiety support the potential clinical meaningfulness of these findings."

Industry Context

StockSavvy.ai notes that Vistagen's announcement highlights the ongoing challenges and opportunities in developing treatments for social anxiety disorder. While the OLE data shows promise for long-term, as-needed use, the failure to meet the primary endpoint in the randomized portion of PALISADE-3 underscores the difficulty in demonstrating efficacy in acute challenge studies for this indication. The company's focus on intranasal 'pherines' represents an innovative approach to neuroscience, aiming for rapid-onset, non-systemic treatments.

Stakeholder Impact

• Shareholders: The mixed results may lead to stock price volatility, with positive sentiment from OLE data tempered by the failure in the randomized trial.
• Patients with Social Anxiety Disorder: The OLE data offers hope for a well-tolerated, as-needed treatment option for managing anxiety in daily life, but the overall efficacy in acute situations remains uncertain.
• Healthcare Providers: Clinicians will need to weigh the OLE's positive long-term safety and improvement data against the negative results from the primary randomized study when considering treatment options.

Next Steps

• Await topline data for the PALISADE-4 Phase 3 trial in Q2 2026.
• Await topline results for the exploratory Phase 2 Repeat Dose Study in Q3 2026.
• Potentially submit an NDA to the FDA if PALISADE-4 is successful and further evidence of clinical meaningfulness is generated.

Key Dates

Recommendation

The company presents a mixed picture. The failure to meet the primary endpoint in the randomized PALISADE-3 study is a significant concern, casting doubt on the drug's efficacy for its intended acute use. However, the positive safety and efficacy trends observed in the open-label extension for longer-term, as-needed use warrant further investigation and suggest potential value. Upcoming data from PALISADE-4 will be critical in determining the drug's future prospects. Given the uncertainty, a 'hold' recommendation is appropriate pending further clarity.

Keywords

Vistagen Therapeutics, Fasedienol, Social Anxiety Disorder, PALISADE-3, Phase 3 Study, Open-Label Extension, Intranasal Spray, Biopharmaceutical